.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AC06_Tesamorelin.Tesamorelin .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AC06_Tesamorelin.Tesamorelin| name: | Tesamorelin |
| ATC code: | H01AC06 | route: | subcutaneous |
| n-compartments | 1 |
Tesamorelin is a synthetic peptide analogue of human growth hormone-releasing factor (GRF/ GHRH) used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It stimulates the pituitary gland to increase the secretion of endogenous growth hormone (GH). Tesamorelin is approved by the FDA for this indication.
Pharmacokinetics in healthy adult volunteers (both sexes, aged 18–55 years) after subcutaneous administration.
González-Sales, M, et al., & Tanguay, M (2015). Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clinical pharmacokinetics 54(3) 285–294. DOI:10.1007/s40262-014-0202-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/25358450
González-Sales, M, et al., & Tanguay, M (2015). Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. Journal of pharmacokinetics and pharmacodynamics 42(3) 287–299. DOI:10.1007/s10928-015-9416-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25895899